Although depressive symptoms are well-known side effects of interferon alpha (IFNα), it is uncertain if these symptoms decline with the cessation of IFNα therapy. We report on a 47-year-old man who, apart from former drug abuse, never had suffered from a psychiatric disorder. However, he had a family history burdened with the suicide of his mother and his twin sister. After a depressive symptomatology during the IFNα therapy, which had been tolerably treated by mirtazapine, he committed a suicide attempt six months after the parallel termination of IFNα and antidepressant treatment. Two aspects of this case report should be emphasised. First, patients with an increased risk for psychiatric complications of interferon therapy must be followed closely for a depressive symptomatology and treated aggressively if symptoms arise. Second, this case report shows the relapse of depressive symptoms far beyond the end of the interferon treatment. If an antidepressant treatment is necessary during IFNα therapy this should not be stopped prematurely with the termination of the interferon medication.
References
-
1
Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C, Clemens J.
Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C.
Psychosomatics.
2001;
42
365-367
-
2
Dieperink E, Ho S B, Thuras P, Willenbring M L.
A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.
Psychosomatics.
2003;
44
104-112
-
3
Fattovich G, Giustina G, Favarato S, Ruol A.
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.
J Hepatol.
1996;
24
38-47
-
4
Fukunishi K, Tanaka H, Maruyama J, Takahashi H, Kitagishi H, Ueshima T ,. et al .
Burns in a suicide attempt related to psychiatric side effects of interferon.
Burns.
1998;
24
581-583
-
5
Gohier B, Goeb J L, Rannou-Dubas K, Fouchard I, Cales P, Garre J B.
Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients.
World J Biol Psychiatry.
2003;
4
115-118
-
6
Janssen H LA, Brouwer J T, van der Mast R C, Schalm S W.
Suicide associated with alfa-interferon therapy for chronic viral hepatitis.
J Hepatol.
1994;
21
241-243
-
7
Kraus M R, Schafer A, Scheurlen M.
Paroxetine for the prevention of depression induced by interferon alfa.
N Engl J Med.
2001;
345
375-376
-
8
Musselman D L, Lawson D H, Gumnick J F, Manatunga A K, Penna S, Goodkin R S,. et al .
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
N Engl J Med.
2001;
344
961-966
-
9
Rifflet H, Vuillemin E, Oberti F, Duverger P, Laine P, Garre J B,. et al .
Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha.
Gastroenterol Clin Biol.
1998;
22
353-357
-
10
Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N ,. et al .
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Hepatology.
2003;
37
443-451
-
11
Williams C D, Linch D C.
Interferon alfa-2a.
Br J Hosp Med.
1997;
57
436-439
Dr. Thomas Nickel
Max Planck Institute of Psychiatry
Kraepelinstr. 10
80804 Munich
Germany
Phone: +49 89 30622 420
Fax: +49 89 30622 605
Email: nickel@mpipsykl.mpg.de
